PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
20.59%
Revenue growth above 1.5x CSIQ's 6.88%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
62.44%
Gross profit growth at 75-90% of CSIQ's 72.29%. Bill Ackman would demand operational improvements to match competitor gains.
-8.26%
Negative EBIT growth while CSIQ is at 25.44%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
0.07%
Operating income growth under 50% of CSIQ's 77.15%. Michael Burry would be concerned about deeper cost or sales issues.
-12.95%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-5.97%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-5.97%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
5.99%
Share count expansion well above CSIQ's 0.01%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.99%
Diluted share count expanding well above CSIQ's 0.01%. Michael Burry would fear significant dilution to existing owners' stakes.
-100.00%
Dividend reduction while CSIQ stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
67.36%
OCF growth of 67.36% while CSIQ is zero. Bruce Berkowitz would see if small gains can expand into a larger competitive lead.
56.05%
FCF growth of 56.05% while CSIQ is zero. Bruce Berkowitz would see if modest improvements in free cash can accelerate further.
440.15%
10Y revenue/share CAGR under 50% of CSIQ's 8987.07%. Michael Burry would suspect a lasting competitive disadvantage.
117.43%
5Y revenue/share CAGR under 50% of CSIQ's 264.28%. Michael Burry would suspect a significant competitive gap or product weakness.
53.55%
3Y revenue/share CAGR under 50% of CSIQ's 152.27%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
-134.86%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-652.07%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1310.38%
Negative 3Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-97.51%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-898.56%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-550.73%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
13.52%
Below 50% of CSIQ's 143.59%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-32.09%
Negative 3Y equity/share growth while CSIQ is at 2.39%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-45.25%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-12.78%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-0.89%
Negative asset growth while CSIQ invests at 17.94%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-12.10%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
20.41%
Debt growth far above CSIQ's 11.96%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-15.68%
Our R&D shrinks while CSIQ invests at 14.12%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-18.00%
We cut SG&A while CSIQ invests at 20.58%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.